DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the President’s Cancer Panel.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: President’s Cancer Panel.

Date: September 22, 2010.

Time: 8 a.m. to 5 p.m.

Place: Hyatt Regency Boston, 1 Ave De Lafayette, Boston, MA 02111.

Contact Person: Abby B. Sandler, PhD, Executive Secretary, Chief, Institute Review Office, Office of the Director, 6116 Executive Blvd., Suite 220, MSC 8349, National Cancer Institute, NIH, Bethesda, MD 20892–8349. (301) 451–9399. sandlera@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute’s/Center’s home page: http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available.

[Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHIS]

Dated: July 15, 2010.

Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–17813 Filed 7–20–10; 8:45 am]
5. Records may be disclosed to appropriate federal agencies and Department contractors that have a need to know the information for the purpose of assisting the Department’s efforts to respond to a suspected or confirmed breach of the security or confidentiality of information maintained in this system of records and the information disclosed is relevant and necessary for that assistance.

DISCLOSURES TO CONSUMER REPORTING AGENCIES:
None.

POLICIES AND PRACTICES FOR STORING, RETRIEVING, ACCESSING, RETAINING AND DISPOSING OF RECORDS IN THE SYSTEM:
STORAGE:
Records in the system are stored electronically.

RETRIEVABILITY:
Records are retrieved by the social security number of the individual to whom the record pertains.

SAFEGUARDS:
Specific administrative, technical, and physical controls are in place to ensure that the records collected and maintained in the FPLS Child Support Services Portal are secure from unauthorized access.

Access to the records is restricted to authorized personnel who are advised of the confidentiality of the records and the civil and criminal penalties for misuse and who sign a nondisclosure oath to that effect. Personnel are provided privacy and security training before being granted access to the records and annually thereafter.

Logistical access controls are in place to limit access to the records to authorized personnel and to prevent browsing. The records are processed and stored in a secure environment. The individual’s SSN is encrypted, and access to, and viewing of, the SSN is restricted to designated employees and contractors of OCSE solely for the purpose of verifying the identity of a registrant or a user of the portal.

All records are stored in an area that is physically safe from access by unauthorized persons at all times.


RECORD ACCESS PROCEDURES:
Individuals seeking access to a record about themselves in this system of records should address written inquiries to the System Manager. The request should include the name, telephone number and/or email address, Social Security number (SSN), and address of the individual. The request must be signed. The requester’s letter must provide sufficient particulars to enable the System Manager to distinguish between records of subject individuals with the same name. Verification of identity as described in the Department’s Privacy Act regulations may be required. 45 CFR 5b.5.

CONTESTING RECORD PROCEDURES:
Individuals seeking to amend a record about themselves in this system of records should address the request for amendment to the System Manager. The request should (1) include the name, telephone number and/or email address, Social Security number (SSN), and address of the individual, and should be signed; (2) identify the system of records that the individual believes includes his
or her records or otherwise provide enough information to enable the identification of the individual’s record; (3) identify the information that the individual believes is not accurate, relevant, timely or complete; (4) indicate what corrective action is sought; and (5) include supporting justification or documentation for the requested amendment. Verification of identity as described in the Department’s Privacy Act regulations may be required. 45 CFR 5b.5.

RECORD SOURCE CATEGORIES:
Information is obtained from individuals and organizations, including third parties conducting business on behalf of a business or organization, that apply for access privileges to the FPLS Child Support Services Portal and its services.

EXEMPTIONS CLAIMED FOR THE SYSTEM:
None.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Safety and Occupational Health Study Section: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through June 30, 2012.

FOR FURTHER INFORMATION CONTACT:
Price Connor, PhD, Executive Secretary, Safety and Occupational Health Study Section, Department of Health and Human Services, 1600 Clifton Road, NE., Mailstop E74, Atlanta, Georgia 30333, telephone 404/498–2511 or fax 404/498–2571.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: July 13, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

[DOCKET NO. FDA–2010–N–0318]
Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 27 new drug applications (NDAs) and 58 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Effective Date: August 20, 2010.


SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 of this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications pursuant to the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

TABLE 1.

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 6–008</td>
<td>Mesantoin (mephenytoin) Tablets</td>
<td>Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936–1080</td>
</tr>
<tr>
<td>NDA 9–000</td>
<td>Cafergot (ergotamine tartrate and caffeine) Suppository, 1 milligram (mg)/100 mg and 2 mg/100 mg</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 9–561</td>
<td>Hypaque (diatrizoate sodium)</td>
<td>GE Healthcare, Inc., 101 Carnegie Center, Princeton, NJ 08540</td>
</tr>
<tr>
<td>NDA 9–658</td>
<td>Hydrocortisone Tablets</td>
<td>Smith, Miller and Patch, Inc., Division of Cooper Vision, Inc., c/o Cooper Laboratories, Inc., 455 E. Middlefield Rd., Mountain View, CA 94043</td>
</tr>
<tr>
<td>NDA 9–942</td>
<td>Deltra (prednisone) Tablets</td>
<td>Merck &amp; Co., Inc., P.O. Box 4, BLA–20, West Point, PA 19486–0004</td>
</tr>
<tr>
<td>NDA 10–051</td>
<td>Hydeltra (prednisolone) Tablets</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 10–255</td>
<td>Meticortelone (prednisolone acetate) Injection and Suspension</td>
<td>Schering Corp., Galloping Hill Rd., Kenilworth, NJ 07033</td>
</tr>
<tr>
<td>NDA 12–885</td>
<td>Winstrol (stanozolol) Tablets, 2 mg</td>
<td>Lundbeck, Inc., Four Parkway North, Deerfield, IL 60015</td>
</tr>
<tr>
<td>NDA 13–428</td>
<td>Valpin (anisotropine methyl bromide) Tablets</td>
<td>Endo Pharmaceuticals, 100 Endo Blvd., Chadds Ford, PA 19317</td>
</tr>
</tbody>
</table>